Arcturus Therapeutics Soars 11.22% on Q1 Earnings, Strategic Shift

On May 13, 2025, Arcturus Therapeutics' stock surged by 11.22% in pre-market trading, reflecting a significant bullish sentiment among investors.

Analysts have given Arcturus Therapeutics a consensus rating of Buy, with a price prediction of $47.94 for 2025. This optimistic outlook is supported by the average target price, which implies a potential upside of 434.94% from the current price.

Arcturus Therapeutics reported its Q1 2025 financials, showing revenues of $29.4 million, a net loss of $14.1 million, and cash and equivalents of $273.8 million. The company also highlighted significant cost reductions in research and development (R&D) and general and administrative (G&A) expenses.

The company's strategic shift toward cystic fibrosis (CF) and over-the-counter (OTC) mRNA therapeutics has extended its cash runway into 2028, providing a stable financial outlook for the near future.